How Medicenna is Developing "Superkines" as Novel Immunotherapies

Rx for Biotech
31/08/2023 29 min
How Medicenna is Developing "Superkines" as Novel Immunotherapies

Listen "How Medicenna is Developing "Superkines" as Novel Immunotherapies"

Descargar episodio Ver en sitio original

Episode Synopsis

In this podcast episode, our guest is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins leveraging their Superkine Platform to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers.

More episodes of the podcast Rx for Biotech

Restoring Breath: Biologic Innovation for the Most Vulenerable Patients 28/10/2025
Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy 14/10/2025
The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies 09/09/2025
Harnessing the Immune System: PDS Biotech’s NextGen Approach to Cancer Treatment 21/08/2025
How Nonacus is Changing Cancer Detection with CEO, Jeff Bousfield 05/08/2025
Hope in Hard Places: A Potential New Option for Patients with Pancreatic Cancer 24/07/2025
How Mesenchymal Stem Cells Are Shaping the Future of Medicine with Dr. Kilian Kelly 03/06/2025
Patient Perspective with CAR-T Cell Therapy Advocate, Brad Watt 08/05/2025
How AI is Transforming Job Search and Recruiting in Life Sciences and Technology 24/04/2025
From Nigeria to the USA: Gene Therapy Journey with Sickle Cell Warrior, Jimi Olaghere 24/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA